Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Change in Accured Expenses (2021 - 2025)

Coeptis Therapeutics Holdings has reported Change in Accured Expenses over the past 5 years, most recently at $295642.0 for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $295642.0 for Q4 2025, up 63.4% from a year ago — trailing twelve months through Dec 2025 was -$115000.0 (down 163.56% YoY), and the annual figure for FY2025 was -$115000.0, down 163.56%.
  • Change in Accured Expenses for Q4 2025 was $295642.0 at Coeptis Therapeutics Holdings, up from -$89967.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for COEPW hit a ceiling of $295642.0 in Q4 2025 and a floor of -$465491.0 in Q4 2021.
  • Median Change in Accured Expenses over the past 5 years was $33964.5 (2021), compared with a mean of $83.2.
  • Biggest five-year swings in Change in Accured Expenses: surged 1732.54% in 2024 and later crashed 298.95% in 2025.
  • Coeptis Therapeutics Holdings' Change in Accured Expenses stood at -$465491.0 in 2021, then soared by 61.72% to -$178178.0 in 2022, then soared by 93.78% to -$11083.0 in 2023, then surged by 1732.54% to $180934.0 in 2024, then soared by 63.4% to $295642.0 in 2025.
  • The last three reported values for Change in Accured Expenses were $295642.0 (Q4 2025), -$89967.0 (Q3 2025), and -$186238.0 (Q2 2025) per Business Quant data.